The new antivirus agent, recently licensed innovation from the University of Belgrade, received 120,000 euros in financial support to continue development in Serbia.
The new antiviral agent was discovered by an international team of researchers led by dr Uroš Anđelković a senior research associate at the Institute of Chemistry, Technology, and Metallurgy.
Serbia Innovation Fund with the support of the European Union Pre-Accession Funds through the early development program approved funding of 80,000 euros for the further development of the new antivirus agent. Finances in the amount of 40,000 euros were provided by private investors and biopharmaceutical companies. The goal of the project is to increase the level of technological readiness in the next 12 months.
The development of a new biopharmaceutical is a long and uncertain process that requires large human and material resources. The project for the development of a new antiviral agent is a pioneer in our area in the field of biological drugs. The help of state funds is of crucial importance in the early phase of drug development. Support for this project of developing a new potential drug is at the same time of great importance for raising the overall level of knowledge and skills of the University and industry in the field of biopharmaceutical development.
The post Financial support for the continued development of licensed technology from the University of Belgrade appeared first on Centar za transfer tehnologije.
